Tags

Type your tag names separated by a space and hit enter

How strong is the association between CAG and GGN repeat length polymorphisms in the androgen receptor gene and prostate cancer risk?
Cancer Epidemiol Biomarkers Prev. 2004 Nov; 13(11 Pt 1):1765-71.CE

Abstract

OBJECTIVE

Although narrative reviews have suggested an association between (CAG)n and (GGN)n polymorphisms in the AR gene and prostate cancer, it has never been quantified systematically. The purpose of this meta-analysis was to provide relative and absolute quantitative summary estimates with sufficient power.

METHOD

Publications were identified through database searches for epidemiologic studies published until February 2004. For each study, mean differences in repeat length between cases and controls were calculated as well as continuous odds ratios (OR) per one CAG or GGN repeat decrement and discrete ORs to compare prostate cancer risk in men with short CAG repeats (</=21 repeats) versus long CAG repeats (>21 repeats) and short GGN repeats (</=16 repeats) versus long GGN repeats (>16 repeats). The study-specific estimates were combined by random effects metaregression analyses.

RESULTS

Nineteen case-control studies were included in this review comprising a total of 4,274 cases and 5,275 controls. Prostate cancer cases had on average 0.26 fewer CAG repeats and 0.09 fewer GGN repeats than controls. The continuous ORs of prostate cancer per one repeat decrement were 1.02 and 1.01 for CAG and GGN repeats, respectively. The summary discrete OR (95% confidence interval) were 1.19 (1.07-1.31) and 1.31 (1.06-1.61) for CAG and GGN repeat polymorphisms, respectively.

CONCLUSION

Although the presence of shorter repeats seemed to be modestly associated with prostate cancer risk, the absolute difference in number of repeats between cases and controls is <1 repeat. We question whether such a small difference is enough to yield measurable biological impact in prostate carcinogenesis.

Authors+Show Affiliations

Department of Public Health and Epidemiology, School of Medicine, Public Health Building, University of Birmingham, Birmingham B15 2TT, United Kingdom. M.P.Zeegers@bham.ac.ukNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Meta-Analysis
Review

Language

eng

PubMed ID

15533905

Citation

Zeegers, Maurice P., et al. "How Strong Is the Association Between CAG and GGN Repeat Length Polymorphisms in the Androgen Receptor Gene and Prostate Cancer Risk?" Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored By the American Society of Preventive Oncology, vol. 13, no. 11 Pt 1, 2004, pp. 1765-71.
Zeegers MP, Kiemeney LA, Nieder AM, et al. How strong is the association between CAG and GGN repeat length polymorphisms in the androgen receptor gene and prostate cancer risk? Cancer Epidemiol Biomarkers Prev. 2004;13(11 Pt 1):1765-71.
Zeegers, M. P., Kiemeney, L. A., Nieder, A. M., & Ostrer, H. (2004). How strong is the association between CAG and GGN repeat length polymorphisms in the androgen receptor gene and prostate cancer risk? Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored By the American Society of Preventive Oncology, 13(11 Pt 1), 1765-71.
Zeegers MP, et al. How Strong Is the Association Between CAG and GGN Repeat Length Polymorphisms in the Androgen Receptor Gene and Prostate Cancer Risk. Cancer Epidemiol Biomarkers Prev. 2004;13(11 Pt 1):1765-71. PubMed PMID: 15533905.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - How strong is the association between CAG and GGN repeat length polymorphisms in the androgen receptor gene and prostate cancer risk? AU - Zeegers,Maurice P, AU - Kiemeney,Lambertus A L M, AU - Nieder,Alan M, AU - Ostrer,Harry, PY - 2004/11/10/pubmed PY - 2005/2/3/medline PY - 2004/11/10/entrez SP - 1765 EP - 71 JF - Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology JO - Cancer Epidemiol Biomarkers Prev VL - 13 IS - 11 Pt 1 N2 - OBJECTIVE: Although narrative reviews have suggested an association between (CAG)n and (GGN)n polymorphisms in the AR gene and prostate cancer, it has never been quantified systematically. The purpose of this meta-analysis was to provide relative and absolute quantitative summary estimates with sufficient power. METHOD: Publications were identified through database searches for epidemiologic studies published until February 2004. For each study, mean differences in repeat length between cases and controls were calculated as well as continuous odds ratios (OR) per one CAG or GGN repeat decrement and discrete ORs to compare prostate cancer risk in men with short CAG repeats (</=21 repeats) versus long CAG repeats (>21 repeats) and short GGN repeats (</=16 repeats) versus long GGN repeats (>16 repeats). The study-specific estimates were combined by random effects metaregression analyses. RESULTS: Nineteen case-control studies were included in this review comprising a total of 4,274 cases and 5,275 controls. Prostate cancer cases had on average 0.26 fewer CAG repeats and 0.09 fewer GGN repeats than controls. The continuous ORs of prostate cancer per one repeat decrement were 1.02 and 1.01 for CAG and GGN repeats, respectively. The summary discrete OR (95% confidence interval) were 1.19 (1.07-1.31) and 1.31 (1.06-1.61) for CAG and GGN repeat polymorphisms, respectively. CONCLUSION: Although the presence of shorter repeats seemed to be modestly associated with prostate cancer risk, the absolute difference in number of repeats between cases and controls is <1 repeat. We question whether such a small difference is enough to yield measurable biological impact in prostate carcinogenesis. SN - 1055-9965 UR - https://www.unboundmedicine.com/medline/citation/15533905/How_strong_is_the_association_between_CAG_and_GGN_repeat_length_polymorphisms_in_the_androgen_receptor_gene_and_prostate_cancer_risk L2 - http://cebp.aacrjournals.org/cgi/pmidlookup?view=long&amp;pmid=15533905 DB - PRIME DP - Unbound Medicine ER -